IHC-CD45 MARKER

The IHC – CD45 Marker test is a specialized immunohistochemistry (IHC) diagnostic test used to detect CD45 (Leukocyte Common Antigen / LCA) expression in tissue samples. CD45 is a protein found on the surface of most white blood cells and is an important marker for identifying hematopoietic (blood-forming) and lymphoid cells.

This test is widely used in pathology to diagnose and classify lymphomas, leukemias, and other hematologic malignancies. Detecting CD45 helps pathologists distinguish lymphoid tumors from non-hematologic tumors such as carcinomas, melanomas, and sarcomas.

CD45 is considered one of the most essential screening markers in hematopathology, especially when evaluating lymph node biopsies or tissue samples with suspected lymphoid malignancy. It is often used along with other markers such as CD3, CD20, CD10, CD15, CD30, and Ki-67 for precise tumor classification.

Benefits of the Test

The CD45 Marker test offers several important clinical benefits:

• Detects leukocyte common antigen expression
• Identifies lymphoid and hematopoietic cells
• Helps diagnose lymphomas and leukemias
• Differentiates hematologic tumors from non-hematologic tumors
• Supports accurate tumor classification
• Guides personalized treatment planning

This test is critical for accurate diagnosis of blood-related cancers.

Why Doctors Recommend This Test

Doctors recommend the CD45 marker test when lymphoma, leukemia, or lymphoid tissue abnormality is suspected.

It is commonly advised for:

• Enlarged lymph node evaluation
• Suspected lymphoma diagnosis
• Tissue biopsy showing atypical lymphoid cells
• Differentiation of hematologic and non-hematologic tumors
• Advanced hematopathology classification

The results help hematologists and oncologists determine the exact nature of the disease and select effective treatment.

Preparation Before Test

No special preparation is required from the patient. The test is performed on previously collected tissue biopsy or surgical specimens.

Normal Reporting Time

The typical turnaround time for the CD45 IHC test is 2 to 5 working days, depending on tissue complexity and laboratory workflow.

Who Should Take This Test

This test is recommended for:

• Patients with enlarged lymph nodes
• Individuals suspected of lymphoma or leukemia
• Patients with abnormal lymphoid tissue findings
• Cases requiring hematologic tumor classification
• Oncology patients needing accurate diagnosis for treatment planning

The IHC CD45 Marker test is a critical diagnostic tool in hematopathology. It helps identify lymphoid cancers accurately, supports precise classification, and enables timely treatment decisions for improved patient outcomes.